These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 18930377)
21. Association of adipokines with metabolic disorders in patients with schizophrenia: Results of comparative study with mental healthy cohort. Tanyanskiy DA; Martynikhin IA; Rotar OP; Konradi AO; Sokolian NA; Neznanov NG; Denisenko AD Diabetes Metab Syndr; 2015; 9(3):163-7. PubMed ID: 25952038 [TBL] [Abstract][Full Text] [Related]
22. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Cerit C; Vural M; Bos Gelmez SÜ; Ozten E; Aker AT; Yıldız M Psychopharmacol Bull; 2010; 43(4):22-36. PubMed ID: 21240150 [TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia. Said MA; Hatim A; Habil MH; Zafidah W; Haslina MY; Badiah Y; Ramli MA; Ananjit S; Sapini Y; Shah M; Mahmud B; Bulgiba A; Hairi NN Prev Med; 2013; 57 Suppl():S50-3. PubMed ID: 23337566 [TBL] [Abstract][Full Text] [Related]
24. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284 [TBL] [Abstract][Full Text] [Related]
25. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. Gunes A; Melkersson KI; Scordo MG; Dahl ML J Clin Psychopharmacol; 2009 Feb; 29(1):65-8. PubMed ID: 19142110 [TBL] [Abstract][Full Text] [Related]
26. Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients. Yun JE; Sull JW; Lee HY; Park E; Kim S; Jo J; Lee SJ; Kim SY; Choi YJ; Jee SH; Huh KB Diabetes Metab Res Rev; 2009 Mar; 25(3):259-65. PubMed ID: 19214966 [TBL] [Abstract][Full Text] [Related]
27. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Klemettilä JP; Kampman O; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Leinonen E Psychiatry Res; 2014 Aug; 218(3):277-83. PubMed ID: 24837425 [TBL] [Abstract][Full Text] [Related]
28. Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment. Peña R; Marquina D; Serrano A; Elfakih Y; de Baptista EA; Carrizo E; Fernández V; Valery L; Teneud L; Baptista T Schizophr Res; 2008 Dec; 106(2-3):315-9. PubMed ID: 18835519 [TBL] [Abstract][Full Text] [Related]
29. The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine. Zhang R; Hao W; Pan M; Wang C; Zhang X; Chen DC; Xiu MH; Yang FD; Kosten TR; Zhang XY Hum Psychopharmacol; 2011 Aug; 26(6):392-6. PubMed ID: 21826737 [TBL] [Abstract][Full Text] [Related]
30. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389 [TBL] [Abstract][Full Text] [Related]
31. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461 [TBL] [Abstract][Full Text] [Related]
32. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Bou Khalil R Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510 [TBL] [Abstract][Full Text] [Related]
33. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ramaswamy K; Masand PS; Nasrallah HA Ann Clin Psychiatry; 2006; 18(3):183-94. PubMed ID: 16923657 [TBL] [Abstract][Full Text] [Related]
34. Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment. Bachmann CJ; Gebhardt S; Lehr D; Haberhausen M; Kaiser C; Otto B; Theisen FM Z Kinder Jugendpsychiatr Psychother; 2012 May; 40(3):151-8; quiz 158-9. PubMed ID: 22532107 [TBL] [Abstract][Full Text] [Related]
35. Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. Tsuneyama N; Suzuki Y; Sawamura K; Sugai T; Fukui N; Watanabe J; Ono S; Saito M; Someya T PLoS One; 2016; 11(3):e0149518. PubMed ID: 26930407 [TBL] [Abstract][Full Text] [Related]
36. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. Richards AA; Hickman IJ; Wang AY; Jones AL; Newell F; Mowry BJ; Whitehead JP; Prins JB; Macdonald GA J Clin Psychopharmacol; 2006 Jun; 26(3):232-7. PubMed ID: 16702887 [TBL] [Abstract][Full Text] [Related]
37. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. Bai YM; Chen JY; Yang WS; Chi YC; Liou YJ; Lin CC; Wang YC; Lin CY; Su TP; Chou P J Clin Psychiatry; 2007 Dec; 68(12):1834-9. PubMed ID: 18162013 [TBL] [Abstract][Full Text] [Related]
38. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Smith RC; Lindenmayer JP; Bark N; Warner-Cohen J; Vaidhyanathaswamy S; Khandat A Int J Neuropsychopharmacol; 2005 Jun; 8(2):183-94. PubMed ID: 15737248 [TBL] [Abstract][Full Text] [Related]
39. Adiponectin independently predicts metabolic syndrome in overweight Latino youth. Shaibi GQ; Cruz ML; Weigensberg MJ; Toledo-Corral CM; Lane CJ; Kelly LA; Davis JN; Koebnick C; Ventura EE; Roberts CK; Goran MI J Clin Endocrinol Metab; 2007 May; 92(5):1809-13. PubMed ID: 17311859 [TBL] [Abstract][Full Text] [Related]
40. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Carrizo E; Fernández V; Quintero J; Connell L; Rodríguez Z; Mosquera M; Acosta A; Baptista T Schizophr Res; 2008 Aug; 103(1-3):83-93. PubMed ID: 18436434 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]